Advanced search
Publication Cover
Future Virology Volume 3, 2008 - Issue 2
Submit an article Journal homepage
1,046
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Poxvirus-Based Vaccine Platforms: Getting at Those Hard-To-Reach Places

Rodolfo Nino-Fonga Institute for Nutrisciences & Health, National Research Council Canada, 550 University Avenue, Charlottetown, PE, C1A 4P3, Canada. [email protected]
&
James B Johnstonb Institute for Nutrisciences & Health, National Research Council Canada, 550 University Avenue, Charlottetown, PE, C1A 4P3, Canada. [email protected]
Pages 99-103 | Published online: 29 Feb 2008

Bibliography

  • Moss B : Poxviridae. In: The Virus and Their Replication. Knipe DM, Howley PM (Eds). Lippincott Williams and Wilkins, Fields Virology, PA, USA 2849–2883 (2001).
  • Moroziewicz D , KaufmanHL: Gene therapy with poxvirus vectors.Curr. Opin. Mol. Ther.7 , 317–325 (2005).
  • Arlen PM , KaufmanHL, DiPaolaRS: Pox viral vaccine approaches.Semin. Oncol.32 , 549–555 (2005).
  • Thorne SH , HwangTH, KirnDH: Vaccinia virus and oncolytic virotherapy of cancer.Curr. Opin. Mol. Ther.7 , 359–365 (2005).
  • Hakim AA , LinPS, WilczynskiS, NguyenK, LynesB, WakabayashiMT: Indications and efficacy of the human papillomavirus vaccine.Curr. Treat. Options Oncol.8(6) , 393–401 (2008).
  • Boyle DB , AndersonMA, AmosR, VoyseyR, CouparBE: Construction of recombinant Fowlpox viruses carrying multiple vaccine antigens and immunomodulatory molecules.Biotechniques37 , 104–111 (2004).
  • Rocha CD , CaetanoBC, MachadoAV, Bruna-RomeroO: Recombinant viruses as tools to induce protective cellular immunity against infectious diseases.Int. Microbiol.7 , 83–94 (2004).
  • Meyer H , SutterG, MayrA: Mapping of deletions in the genome of the highly attenuated Vaccinia virus MVA and their influence on virulence.J. Gen. Virol.72(Pt 5) , 1031–1038 (1991).
  • Tartaglia J , PerkusME, TaylorJ et al.: NYVAC: a highly attenuated strain of Vaccinia virus. Virology188 , 217–232 (1992).
  • Plotkin SA , CadozM, MeignierB et al.: The safety and use of canarypox vectored vaccines. Dev. Biol. Stand.84 , 165–170 (1995).
  • Skinner MA , LaidlawSM, EldaghayesI, KaiserP, CottinghamMG: Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry.Expert Rev. Vaccines4 , 63–76 (2005).
  • Rziha HJ , HenkelM, CottoneR, MeyerM, DehioC, ButtnerM: Parapoxviruses: potential alternative vectors for directing the immune response in permissive and non-permissive hosts.J. Biotechnol.73 , 235–242 (1999).
  • Black DN : Capripoxvirus-based multivaccines.Dev. Biol. Stand.84 , 179–182 (1995).
  • Kreijtz JH , SuezerY, van Amerongen G et al.: Recombinant modified Vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J. Infect. Dis.195 , 1598–1606 (2007).
  • McShane H , PathanAA, SanderCR et al.: Recombinant modified Vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med.10 , 1240–1244 (2004).
  • Miao J , LiX, LiuZ, XueC, BujardH, CuiL: Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified Vaccinia Ankara vaccines.Vaccine24 , 6187–6198 (2006).
  • Boursnell ME , RutherfordE, HicklingJK et al.: Construction and characterisation of a recombinant Vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine14 , 1485–1494 (1996).
  • Lindsey KR , GritzL, SherryR et al.: Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clin. Cancer Res.12 , 2526–2537 (2006).
  • Arlen PM , GulleyJL: Therapeutic vaccines for prostate cancer: a review of clinical data.Curr. Opin. Investig. Drugs6 , 592–596 (2005).
  • Meyer RG , BrittenCM, SiepmannU et al.: A Phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified Vaccinia virus Ankara (MVA-hTyr).Cancer Immunol. Immunother.54 , 453–467 (2005).
  • Bejon P , MwacharoJ, KaiO et al.: A Phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin. Trials1 , e29 (2006).
  • Russell ND , GrahamBS, KeeferMC et al.: Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a Phase 3 correlates trial.J. Acquir. Immune Defic. Syndr.44 , 203–212 (2007).
  • Blancou J , KienyMP, LatheR et al.: Oral vaccination of the fox against rabies using a live recombinant Vaccinia virus. Nature322 , 373–375 (1986).
  • Marsland BJ , TisdallDJ, HeathDD, MercerAA: Construction of a recombinant orf virus that expresses an Echinococcus granulosus vaccine antigen from a novel genomic insertion site.Arch. Virol.148 , 555–562 (2003).
  • Shen G , JinN, MaM et al.: Immune responses of pigs inoculated with a recombinant Fowlpox virus coexpressing GP5/GP3 of porcine reproductive and respiratory syndrome virus and swine IL-18.Vaccine5 , 4193–4202 (2007).
  • Fischer T , PlanzO, StitzL, RzihaHJ: Novel recombinant parapoxvirus vectors induce protective humoral and cellular immunity against lethal herpesvirus challenge infection in mice.J. Virol.77 , 9312–9323 (2003).
  • Bublot M , PritchardN, SwayneDE et al.: Development and use of fowlpox vectored vaccines for avian influenza.Ann. NY Acad. Sci.1081 , 193–201 (2006).
  • Poulet H , MinkeJ, PardoMC, JuillardV, NordgrenB, AudonnetJC: Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform.Vaccine25 , 5606–5612 (2007).
  • Tuteja R : Malaria – an overview.FEBS J.274 , 4670–4679 (2007).
  • Ballou WR , Arevalo-HerreraM, CarucciD et al.: Update on the clinical development of candidate malaria vaccines.Am. J. Trop. Med. Hyg.71 , 239–247 (2004).
  • Hutchings CL , GilbertSC, HillAV, MooreAC: Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity.J. Immunol.175 , 599–606 (2005).
  • Ockenhouse CF , SunPF, LanarDE et al.: Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.J. Infect. Dis.177 , 1664–1673 (1998).
  • Tine JA , LanarDE, SmithDM et al.: NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect. Immun.64 , 3833–3844 (1996).
  • Webster DP , DunachieS, VuolaJM et al.: Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified Vaccinia virus Ankara. Proc. Natl Acad. Sci. USA102 , 4836–4841 (2005).
  • McConkey SJ , ReeceWH, MoorthyVS et al.: Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified Vaccinia virus Ankara in humans. Nat. Med.9 , 729–735 (2003).
  • Weiss WR , KumarA, JiangG et al.: Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens. PLoS ONE2 , E1063 (2007).
  • Cho MW , KimYB, LeeMK et al.: Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.J. Virol.75 , 2224–2234 (2001).
  • Cooney EL , CollierAC, GreenbergPD et al.: Safety of and immunological response to a recombinant Vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet337 , 567–572 (1991).
  • Evans TG , KeeferMC, WeinholdKJ et al.: A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J. Infect. Dis.180 , 290–298 (1999).
  • Goonetilleke N , MooreS, DallyL et al.: Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified Vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.J. Virol.80 , 4717–4728 (2006).
  • Shinoda K , XinKQ, KojimaY, SahaS, OkudaK, OkudaK: Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant Vaccinia virus (LC16m8 strain) boost.Clin. Immunol.119 , 32–37 (2006).
  • Harrer E , BauerleM, FerstlB et al.: Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.Antivir. Ther.10 , 285–300 (2005).
  • Naito T , KanekoY, KozborD: Oral vaccination with modified Vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization.J. Gen. Virol.88 , 61–70 (2007).
  • McKee HJ , T‘saoPY, VeraM, FortesP, StrayerDS: Durable cytotoxic immune responses against gp120 elicited by recombinant SV40 vectors encoding HIV-1 gp120 +/- IL-15.Genet. Vaccines Ther.2 , 10 (2004).
  • Giavedoni LD , JonesL, GardnerMB et al.: Vaccinia virus recombinants expressing chimeric proteins of human immunodeficiency virus and γ interferon are attenuated for nude mice.Proc. Natl Acad. Sci. USA89 , 3409–3413 (1992).
  • Belyakov IM , MossB, StroberW, BerzofskyJA: Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity.Proc. Natl Acad. Sci. USA96 , 4512–4517 (1999).
  • Hanke T , McMichaelAJ, DorrellL: Clinical experience with plasmid DNA- and modified Vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.J. Gen. Virol.88 , 1–12 (2007).
  • Gomez CE , NajeraJL, JimenezEP et al.: Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine25 , 2863–2885 (2007).
  • Okamura T , SomeyaK, MatsuoK, HasegawaA, YamamotoN, HondaM: Recombinant vaccinia DIs expressing simian immunodeficiency virus gag and pol in mammalian cells inducesefficient cellular immunity as a safe immunodeficiency virus vaccine candidate.Microbiol. Immunol.50 , 989–1000 (2006).
  • Viner KM , GirgisN, KwakH, IsaacsSN: B5-deficient Vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals.Virology361 , 356–363 (2007).
  • Moingeon P : Recombinant cancer vaccines based on viral vectors.Dev. Biol. (Basel)116 , 117–122 (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.